Dianthus Therapeutics, Inc. /DE/

The company is a clinical-stage biotechnology firm dedicated to creating targeted therapies for individuals affected by severe autoimmune conditions. Its pipeline focuses on investigational candidates, led by claseprubart, an engineered monoclonal antibody that selectively inhibits active C1s complement protein, and DNTH212, a bifunctional fusion protein targeting BDCA2 and BAFF/APRIL. Through these biological agents, the enterprise targets disorders such as generalized Myasthenia Gravis, Chronic Inflammatory Demyelinating Polyneuropathy, and Multifocal Motor Neuropathy, with intended end users being patients suffering from complement-dependent and related neuroinflammatory disorders.

The company operates globally through clinical trial programs across multiple regions, retaining worldwide commercialization rights outside of Greater China, where rights are out-licensed to regional partners. It maintains intellectual property protections across numerous jurisdictions, including the United States, Europe, Canada, Japan, and other international territories. The business does not own manufacturing facilities, instead relying entirely on third-party contract organizations, and the provided excerpt does not state its headquarters location.

Summary of the business section of Dianthus Therapeutics's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of March 4, 2026, we had 92 employees, all of whom were employed full time and 66 of whom were engaged in research and development activities.”